
ELSEVIER

Available online at www.sciencedirect.com


Bioorganic & Medicinal Chemistry Letters 16 (2006) 815–820

Bioorganic & Medicinal Chemistry Letters

Synthesis and antiprotozoal activity of some new synthetic substituted quinoxalines

Xu Hui,[†] Julie Desrivot, Christian Bories, Philippe M. Loiseau, Xavier Franck, Reynald Hocquemiller and Bruno Figadère*

Address Laboratoire de Pharmacognosie et Groupe Chimiothérapie Antiparasitaire (associé au CNRS-BioCIS) Faculté de Pharmacie, Université de Paris-Sud, rue J.B. Clément, 92296 Châtenay-Malabry, France

Received 10 October 2005; revised 7 November 2005; accepted 7 November 2005
Available online 23 November 2005

Abstract—A series of 29 new quinoxalines was synthesized and evaluated in vitro against several parasites (*Leishmania donovani*, *Trypanosoma brucei brucei*, and *Trichomonas vaginalis*). Several of them displayed interesting activities, and particularly four quinoxaline amides showed in vitro antileishmanial properties (IC_{50} less than 20 μM).
© 2005 Elsevier Ltd. All rights reserved.

Several hundred millions of people, in developing countries, faced infection diseases, due to parasites, such as leishmaniases and trypanosomiasis that have significant health and economical impacts because of a high mortality rate per year. There is, thus, an urgent need for new drugs for the chemotherapy of these diseases, since conventional treatments are often inadequate, toxic or are becoming less effective due to emergence of numerous resistances.[1]

In our search for new bioactive compounds, we have found that 2-alkylquinolines and 2-arylquinolines, isolated from plants[2] or prepared by total synthesis,[3a–c] can be new drug candidates, and exhibit antiprotozoal activity (e.g., against *Leishmania* sp.,[4] *Plasmodium*,[5] *Trypanosoma* sp.,[6] and *Trichomonas vaginalis*[7]), and were found to inhibit the human immunodeficiency virus of type-1 (HIV-1) integrase,[8–10] as well as the proliferation of HTLV-1 transformed cell lines (HUT-102).[11] In this letter, in continuation of the search for new antiparasitic compounds, we report on the in vitro antiprotozoal activity of several synthetic substituted quinoxalines.

Up to now, only a few quinoxaline derivatives have been prepared and evaluated against protozoa,[12] whereas quinoxaline derivatives are important components of several pharmacologically active compounds.[13] In this paper, we carried out new pharmacomodulations including substituents having antiprotozoal properties such as quinoline, and *p*-nitrophenyl moieties or substituents modifying the hydrophobicity of the compounds, such as alkyl chains (C6 to C15) and various aromatic rings. Thus, new quinoxaline amides and amines **1**–**29** were prepared by treating 2-amino-4-nitroaniline with several 1,2-dioxoalkanes (1 equiv.)[14] followed by nitro-reduction and either amide formation (compounds **1**–**8**) or reductive amination (for compounds **14**–**18**) (Scheme 1). For the bromo derivatives, bromination of the intermediate 7-aminoquinoxaline was performed prior to amide formation (compounds **9**–**13**, Scheme 1). Whereas quinoxalines **19**–**29** were obtained by condensation of 2-amino-4-aminobenzoic acid with several 1,2-dioxoalkanes (1 equiv) followed by amide formation (compounds **19**–**29**, Scheme 2). All the 29 synthesized compounds gave satisfactory spectral data (^1H and ^{13}C NMR data, MS and UV spectroscopic data). Then compounds **1**–**29** were evaluated against several parasites (*Leishmania donovani*, *Trypanosoma brucei brucei*, and *T. vaginalis*).

Antiprotozoal activities of the synthesized quinoxalines **1**–**29** are presented in Table 1. Against the promastigote forms of *L. donovani*[15] compounds **5**, **6**, **7**, and **27** were the most active ones (with IC_{50}: 12.5, 8.2, 18.5, and 18.4 μM, respectively) being slightly less potent than the reference drug, miltefosine (IC_{50}: 7.3 μM). Interestingly, compounds **26**, **27**, and **28** in which the amide

Keywords: Quinoxalines; Amides; Amines; Synthesis; Bioassays.
* Corresponding author. Tel.: +33 01 46 83 55 92; fax: +33 01 46 83 53 99; e-mail: bruno.figadere@cep.u-psud.fr
[†] Present address: College of Life Science, Northwest Sci-Tec University of Agriculture and Forestry, China.

0960-894X/$ - see front matter © 2005 Elsevier Ltd. All rights reserved.
doi:10.1016/j.bmcl.2005.11.025

Scheme 1. Reagents and condition: Synthesis of quinoxalines **1**–**18**: (a) HOAc or EtOH reflux; (b) $SnCl_2$, EtOH; (c) Br_2, HOAc; (d) EDC, HOBt, Et_3N or oxalyl chloride then Et_3N, RCO_2H, RNH_2; (e) $NaBH_3CN$, HOAc, RCHO.

bond has been inverted showed different activities (IC_{50}: >300, 18.4, >300 μM, respectively). However, the amide group position did not seem to be essential for antileishmanial properties since compound **27** had similar activity as compound **7**. The sole other quinoxaline amide showing some activity is compound **2** (IC_{50}: 116.9 μM) possessing a simple aliphatic side chain. Then aminoquinoxalines **14**, **15**, **16**, and **18** showed moderate activity (IC_{50}: 79.5, 92.4, 46.3, and 34.0 μM, respectively), but to a lesser extent that the previous compounds. All other tested quinoxalines did not show any activity against *L. donovani*. The tests against the trypomastigote forms of *T. b. brucei* were performed as described.[16] The same compounds **27**, **5**, **6**, and **7** showed again activity, expressed as minimum active concentration (MAC: 200, 200, 200, and 150 μM, respectively), but were by far less active than melarsoprol, the reference drug (MAC: 0.1 μM). Although the quinoxaline amide derivative **24** showed also a slight activity (MAC: 200 μM), all other quinoxalines did not show any particular activity (MAC >300 μM). Against *T. vaginalis*,[17] the aminoquinoxalines **15**, **16**, **17** and the amide **7** showed an activity (IC_{50}: 264, 243, 191, and 126 μM, respectively), being still less potent than the reference drug, metronidazole (IC_{50}: 5.8 μM), whereas the other compounds showed no activity.

Concerning the specificity of action, compounds **2**, **14**, and **18** specifically act on *L. donovani* promastigotes, compound **24** on *T. b. brucei* trypomastigotes, and compound **17** on *T. vaginalis*, suggesting the possibility of action on target specific to each parasite. However, compounds **7** act in the same way against the three Protozoa, suggesting that this compound could affect target(s) common to the three parasites. The difference in these activities could also be the result of compound uptake that is different in these parasites.

In conclusion, this study showed that among the 29 quinoxalines tested in these assays, four of them were found to exhibit interesting antileishmanial activity against *L. donovani* (IC_{50} less than 20 μM), five of them against *T. b. brucei*, and four of them against *T. vaginalis*. No clear-cut structure–activity relationship emerged in this series although, none of the brominated quinoxalines displayed any activity, neither any

$R^1 = R^2 = Ph$: 77%
$R^1 = R^2 = H$: 79%
$R^1 = R^2 = Me$: 87%
$R^1 = H, R^2 = Me$: 38%

Scheme 2. Reagents and condition: Synthesis of quinoxalines **19**–**29**: (a) HOAc or EtOH reflux; (b) EDC, HOBt, Et_3N or oxalyl chloride then Et_3N, RCO_2H, RNH_2.

Table 1. Antiprotozoal activities of quinoxalines **1**–**29**

Compound	*L. donovani*[a] $IC_{50} \pm SEM$ (μM)	*T. b. brucei*[b] MAC (μM)	*T. vaginalis*[c] $IC_{50} \pm SEM$ (μM)
1	>300	>300	>300
2	116.9 ± 7.3	>300	>300
3	>300	>300	>300
4	>300	>300	>300
5	12.5 ± 0.6	200	>300

(*continued on next page*)

Table 1 (*continued*)

Compound	*L. donovani*[a] IC_{50} ± SEM (μM)	*T. b. brucei*[b] MAC (μM)	*T. vaginalis*[c] IC_{50} ± SEM (μM)
6	8.2 ± 0.7	200	>300
7	18.5 ± 1.0	150	126 ± 17
8	>300	>300	>300
9	>300	>300	>300
10	>300	>300	>300
11	>300	>300	>300
12	>300	>300	>300
13	>300	>300	>300
14	79.5 ± 2.9	>300	>300
15	92.4 ± 5.4	>300	264 ± 15
16	46.3 ± 2.0	>300	243 ± 26
17	>300	>300	191 ± 27
18	34.0 ± 4.4	>300	>300
19	>300	>300	>300
20	>300	>300	>300

Table 1 (*continued*)

Compound	*L. donovani*[a] IC_{50} ± SEM (μM)	*T. b. brucei*[b] MAC (μM)	*T. vaginalis*[c] IC_{50} ± SEM (μM)
21	>300	>300	>300
22	>300	>300	>300
23	>300	>300	>300
24	>300	200	>300
25	>300	>300	>300
26	>300	>300	>300
27	18.4 ± 1.4	200	>300
28	>300	>300	>300
29	>300	>300	>300
Miltefosine	7.3 ± 0.7	ND	ND
Melarsoprol	ND	0.1	ND
Metronidazole	ND	ND	5.8 ± 0.6

[a] *Leishmania donovani* strain MHOM/ET/L82/LV9.
[b] *Trypanosoma brucei brucei* GVR 35.
[c] *Trichomonas vaginalis* strain CMP; ND, not determined.

2,3-diphenylquinoxaline, and only two retroamide on 11 ones were active. Further studies will now be undertaken to evaluate their in vitro cytotoxicity on mammal cells and in vivo activity.

Acknowledgments

CNRS is acknowledged for financial support, and thanks are due to Blandine Seon-Meniel for her technical help and to J.-J. Jullian for the NMR experiments. We wish to thank Dr. A. Fournet for fruitful discussion in this area. The Ministère de la Recherche is acknowledged for a fellowship to X.H. through the *GenHomme* ACI, as well as PhytoSynthèse company for a financial support to J.D.

References and notes

1. Antoine, J. C.; Jouanne, C.; Ryter, A. *Parasitology* **1989**, *99*, 1.

2. (a) Fournet, A.; Hocquemiller, R.; Roblot, F.; Cavé, A.; Richomme, P.; Bruneton, J. *J. Nat. Prod.* **1993**, *56*, 1547; (b) Fournet, A.; Vagneur, B.; Richomme, P.; Bruneton, J. *Can. J. Chem.* **1989**, *67*, 2116.
3. (a) Fakhfakh, M. A. PhD Thesis; University of Pari-Sud: Châtenay-Malabry, France, 2001; (b) Fakhfakh, M. A.; Franck, X.; Fournet, A.; Hocquemiller, R.; Figadère, B. *Tetrahedron Lett.* **2001**, *42*, 3847; (c) Fakhfakh, M. A.; Franck, X.; Hocquemiller, R.; Figadère, B. *J. Organomet. Chem.* **2001**, *624*, 131; (d) Fakhfakh, M. A.; Franck, X.; Fournet, A.; Hocquemiller, R.; Figadère, B. *Synth. Commun.* **2002**, *32*, 2863; (e) Seck, M.; Franck, X.; Hocquemiller, R.; Figadère, B.; Peyrat, J. F.; Provot, O.; Brion, J. D.; Alami, M. *Tetrahedron Lett.* **2004**, *45*, 1881.
4. Fournet, A.; Ferreira, M. E.; Torres de Ortiz, S.; Fuentes, S.; Nakayama, H.; Rojas de Arias, A.; Schinini, A.; Hocquemiller, R. *Antimicrob. Agents Chemother.* **1996**, *40*, 2447.
5. Gantier, J. C.; Fournet, A.; Munos, M. H.; Hocquemiller, R. *Planta Med.* **1996**, *62*, 285.
6. Nakayama, H.; Ferreira, M. E.; Rojas de Arias, A.; de Bilbao, N. V.; Schinini, A.; Fournet, A. *Phytother. Res.* **2001**, *15*, 630.
7. Martínez-Grueiro, M.; Giménez-Pardo, C.; Gómez-Barrio, A.; Franck, X.; Fournet, A.; Hocquemiller, R.; Figadère, B.; Casado-Escribano, N. *Il Farmaco* **2005**, *60*, 219.
8. Mekouar, K.; Mouscadet, J. F.; Desmaële, D.; Subra, F.; Leh, H.; Savouré, D.; Auclair, C.; d'Angelo, J. *J. Med. Chem.* **1998**, *41*, 2846.
9. Zouhiri, F.; Mouscadet, J. F.; Mekouar, K.; Desmaële, D.; Savouré, D.; Leh, H.; Subra, F.; Le Bret, M.; Auclair, C.; d'Angelo, J. *J. Med. Chem.* **2000**, *43*, 1533.
10. Fakhfakh, M. A.; Prina, E.; Mouscadet, J. F.; Fournet, A.; Franck, X.; Hocquemiller, R.; Figadère, B. *Bioorg. Med. Chem.* **2003**, *11*, 5013.
11. (a) Fournet, A.; Mahieux, R.; Fakhfakh, M. A.; Franck, X.; Hocquemiller, R.; Figadère, B. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 891; (b) Franck, X.; Fournet, A.; Prina, E.; Mahieux, R.; Hocquemiller, R.; Figadère, B. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 3635.
12. (a) Kim, A. K.; Miller, L. F.; Bambury, R. E.; Ritter, H. W. *J. Med. Chem.* **1977**, *20*, 557; (b) Sastry, C. V. R.; Jogibhukta, M.; Krishnan, V. S. H.; Rao, P. S.; Vemana, K.; Shridar, D. R.; Tripathi, R. M.; Verma, R. K.; Kaushal, R. *Indian J. Chem., Sect. B* **1988**, *27B*, 1110; (c) Sastry, C. V. R.; Marwah, P.; Marwah, A. K.; Rao, G. S. *Indian J. Chem., Sect. B* **1989**, *28B*, 885.
13. (a) More, S. V.; Sastry, M. N. V.; Wang, C.-C.; Yao, C.-F. *Tetrahedron Lett.* **2005**, *46*, 6345; (b) Balandina, A.; Kalinin, A.; Mamedov, V.; Figadère, B.; Latypov, Sh. *Magn. Reson. Chem.* **2005**, *43*, 816; (c) Arthur, G.; Elor, K. B.; Robert, G. S.; Guo, Z. Z.; Richard, J. P.; Stanley, D.; John, R. K.; Sean, T. *J. Med. Chem.* **2005**, *48*, 744; (d) Jaso, A.; Zarranz, B.; Aldana, I.; Monge, A. *J. Med. Chem.* **2005**, *48*, 2019; (e) Lainne, E. S.; William, J. S.; Robert, C. R. *J. Med. Chem.* **2002**, *45*, 5604; (f) Ali, M. M.; Ismail, M. M. F.; EI-Gabby, M. S. A.; Zahran, M. A.; Ammar, T. A. *Molecules* **2000**, *5*, 864; (g) Sakata, G.; Makino, K.; Kurasawa, Y. *Heterocycles* **1998**, *27*, 2481.
14. Brown, D. J. In *The Chemistry of Heterocyclic Compounds*; Taylor, E. C., Wipf, P., Eds.; Wiley: New Jersey, 2004.
15. M'Bongo, N.; Loiseau, P.; Lawrence, F.; Bories, C.; Robert-Gero, M. *Parasitol. Res.* **1997**, *83*, 515, Briefly, promastigotes of *L. donovani* were grown at 27 °C under a 5% CO_2 atmosphere in M199 medium containing 10% fetal calf serum (FCS) and supplemented with 40 mM HEPES, 100 μM adenosine, 0.5 mg hemin per liter, and 50 μg gentamycin per mL. The test was performed in 96-well microtiter plates at 27 °C under a 5% CO_2 atmosphere in the dark. Two hundred microliters of culture medium was placed in the well containing the maximum concentration of extract (C1), and 100 μL in the following (C2 to C7 and controls); 2 μL of an extract solution of 20 mg/mL in DMSO was added in C1 and a serial dilution in the wells was performed. After 1 h at 27 °C under a 5% CO_2 atmosphere, 100 μL of culture medium complemented with 1.75×10^6 leishmania/mL, from a logarithmic phase culture, was added. The final volume in the well was 200 μL. Biological tests were performed three times and each tested concentration in triplicate. The viability of parasites was evaluated by the tetrazolium-dye (MTT) colorimetric method. The results are expressed as the concentration inhibiting parasite growth by 50% (IC_{50}) after a 72 h incubation period.
16. Loiseau, P.; Lubert, P.; Wolf, J. G. *Antimicrob. Agents Chemother.* **2000**, *44*, 2954, Briefly, the bloodstream forms of *T. b. brucei* were maintained in vitro for 48 h in the dark at 37 °C in a 5% CO_2 atmosphere, in minimum essential medium (Gibco-BRL) including 25 mM HEPES and Earle's salts, and supplemented with 2 mM L-glutamine, 1 g of additional glucose per liter, 10 mL of minimum essential medium nonessential amino acids (100×; Gibco-BRL) per liter, 0.2 mM 2-mercaptoethanol, 2 mM sodium pyruvate, 0.1 mM hypoxanthine, 0.016 mM thymidine, 15% heat-inactivated horse serum (Gibco-BRL), and 50 μg gentamycin per mL. The 96-well plates were filled up just like in the leishmanicidal assay, except that the culture medium was complemented with 2×10^5 trypomastigotes from the blood of a mouse collected aseptically from the retro-orbital sinus. The minimum active concentration (MAC) was defined as the minimum concentration at which no viable parasite was observed microscopically.
17. Loiseau, P.; Bories, C.; Sanon, A. *Arzneimittel-Forschung* **1999**, *49*, 51, Briefly, *T. vaginalis* were grown in TYM medium for 48 h in the dark at 35 °C in a 5% CO_2 atmosphere. The 96-well plates were filled up like in the antileishmanial assay, except that the final volume was 300 μL. A 400 μL volume of culture medium was placed in the well containing the maximum concentration of extract (C1), and 200 μL in the following (C2 to C7 and controls); 3 μL of an extract solution at 20 mg/mL in DMSO was added in C1 and a serial dilution in the wells was performed. After 1 h at 35 °C under a 5% CO_2 atmosphere, 100 μL of culture medium complemented with 12×10^4 trichomonas/mL, from a logarithmic phase culture, was added in each well. Biological tests were performed three times, and each tested concentration in triplicate. The 50% Inhibitory Concentration (IC_{50}) was defined microscopically and/or using bromophenol purple.